Every clinical trial needs a protocol, alongside other documents in the submission package. But a protocol only works well when it connects the science with the practical reality of running the trial. For one biotech company developing a first-in-human trial for a novel Central nervous system (CNS) therapy, that meant bringing several perspectives together from the start. This included the sponsor’s scientific objectives and site feasibility with input from our clinical pharmacology unit experts, clinical operations, bioanalysis, regulatory expectations, pharmacovigilance, pharmacokinetics and biostatistics.
We supported the client with protocol development as part of a broader full-service trial set-up, combining medical writing with our Phase I consultancy services. Our role went beyond producing the required document. Our medical writer aligned input across the sponsor and our teams to create a functional protocol for the people responsible for trial start-up, conduct, statistical analysis and clinical study reporting.
The challenge: keeping the protocol connected to all stakeholders
Protocol development brings several questions together at once. What does the sponsor want to assess? What is feasible for sites and bioanalysis laboratories? What does clinical operations need to prepare the trial? What information is crucial to have the protocol approved after regulatory and ethical review? How will the planned data be collected, analyzed and reported?
If these questions move through separate workstreams, gaps can emerge. A protocol can look complete on paper, yet still create issues downstream during regulatory review and in trial start-up documents, operational planning, data interpretation or the clinical study report.
This is particularly relevant in CNS development, where decisions around CNS exposure, biomarkers, patient selection, endpoints and recruitment feasibility can shape development risk from an early stage. Explore the main challenges in CNS clinical trials and how to address them earlier in development.
For this first-in-human trial, the challenge was to keep the protocol clear, complete, practically feasible and aligned with the wider trial path. Timelines also needed flexibility to account for the availability of essential data and the development of supporting documents.
The approach: medical writing working with sponsor and SGS team
We supported the sponsor through one connected full-service set-up, with our medical writing, clinical operations, pharmacokinetics, biostatistics, data management, regulatory support, pharmacovigilance and clinical pharmacology unit experts working closely together on the trial.
Our medical writer contributed more than writing by bringing together input from the sponsor and across our team. That is where our approach differs from a more distant and siloed clinical research organization (CRO) model. Rather than simply processing comments and moving the document to the next review step, our medical writers review the protocol critically. This involves checking that the trial logic is sound, the approach feasible and the protocol makes sense during start-up, data collection, statistical analysis and reporting.
That critical review was stronger because the team worked under one roof, with short communication lines between our experts and the medical writer. Questions could be checked directly with colleagues who understood the scientific, operational, data-related and regulatory consequences of protocol choices. This helped identify blind spots and potential issues earlier in the writing process. When comments needed clarification, feasibility had to be checked or perspectives needed alignment, our writer could involve the relevant expert colleagues swiftly and help move the discussion toward a clear decision.
The impact: confidence that carried into downstream trial assets
After protocol writing, the sponsor asked to work with the same medical writer again for the clinical study report. That request is an important proof point. It shows the client’s confidence in the writer’s understanding of the trial, the efficiency brought to coordinating input and the continuity carried from the protocol stage into later documentation.
For the clinical study report, that continuity matters. The clinical study report needs to bring together the trial objectives, methods, data and interpretation in one clear story. When the writer already understands the protocol logic behind earlier decisions, the reporting process starts from a stronger position. There is less need to rebuild context or risk that important rationales get lost between project stages.
The conclusion: connected CRO support where it matters
For pharma and biotech teams, this is where we bring added value: delivering trial documents that are kept connected to the decisions behind them.
This case shows how our medical writers work closely with colleagues in pharmacokinetics, biostatistics, clinical operations, regulatory support, pharmacovigilance, and our clinical pharmacology unit. That connected approach helps us check the trial logic, challenge assumptions and align the documentation with scientific intent, operational feasibility, site reality, data collection, statistical analysis and later reporting.
The result is documentation that is not only complete, but clearer, more consistent and better prepared for the next steps of the trial.
